Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Xuxu Gou, PhD

Title(s)Postdoctoral Scholar, HDF Comprehensive Cancer Ctr
SchoolSchool of Medicine
Address600 16th Street
San Francisco CA 94158
Emailxuxu.gou@ucsf.edu
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models. Mol Cancer Ther. 2025 Jan 02; 24(1):56-68. Chen H, Gou X, Mao Y, O'Leary PC, Diolaiti ME, Ashworth A. PMID: 39313957.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    2. PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510. Chen A, Kim BJ, Mitra A, Vollert CT, Lei JT, Fandino D, Anurag M, Holt MV, Gou X, Pilcher JB, Goetz MP, Northfelt DW, Hilsenbeck SG, Marshall CG, Hyer ML, Papp R, Yin SY, De Angelis C, Schiff R, Fuqua SAW, Ma CX, Foulds CE, Ellis MJ. PMID: 38781103; PMCID: PMC11443213.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    3. De novo design of drug-binding proteins with predictable binding energy and specificity. Science. 2024 04 05; 384(6691):106-112. Lu L, Gou X, Tan SK, Mann SI, Yang H, Zhong X, Gazgalis D, Valdiviezo J, Jo H, Wu Y, Diolaiti ME, Ashworth A, Polizzi NF, DeGrado WF. PMID: 38574125; PMCID: PMC11290694.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    4. De novo design of drug-binding proteins with predictable binding energy and specificity. bioRxiv. 2023 Dec 23. Lu L, Gou X, Tan SK, Mann SI, Yang H, Zhong X, Gazgalis D, Valdiviezo J, Jo H, Wu Y, Diolaiti ME, Ashworth A, Polizzi NF, DeGrado WF. PMID: 38187746; PMCID: PMC10769398.
      View in: PubMed   Mentions:
    5. Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer. Cancer Res. 2023 10 02; 83(19):3237-3251. Gou X, Kim BJ, Anurag M, Lei JT, Young MN, Holt MV, Fandino D, Vollert CT, Singh P, Alzubi MA, Malovannaya A, Dobrolecki LE, Lewis MT, Li S, Foulds CE, Ellis MJ. PMID: 37071495; PMCID: PMC10543968.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    6. Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov. 2022 11 02; 12(11):2586-2605. Anurag M, Jaehnig EJ, Krug K, Lei JT, Bergstrom EJ, Kim BJ, Vashist TD, Huynh AMT, Dou Y, Gou X, Huang C, Shi Z, Wen B, Korchina V, Gibbs RA, Muzny DM, Doddapaneni H, Dobrolecki LE, Rodriguez H, Robles AI, Hiltke T, Lewis MT, Nangia JR, Nemati Shafaee M, Li S, Hagemann IS, Hoog J, Lim B, Osborne CK, Mani DR, Gillette MA, Zhang B, Echeverria GV, Miles G, Rimawi MF, Carr SA, Ademuyiwa FO, Satpathy S, Ellis MJ. PMID: 36001024; PMCID: PMC9627136.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    7. Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Res. 2021 12 15; 81(24):6259-6272. Gou X, Anurag M, Lei JT, Kim BJ, Singh P, Seker S, Fandino D, Han A, Rehman S, Hu J, Korchina V, Doddapaneni H, Dobrolecki LE, Mitsiades N, Lewis MT, Welm AL, Li S, Lee AV, Robinson DR, Foulds CE, Ellis MJ. PMID: 34711608; PMCID: PMC9234971.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    Xuxu's Networks
    Concepts (49)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (3)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-16-gff1bd585 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.